Nanomedic Registers SpinCare with UK NHS, Expands to 34 Countries; India Launch and US FDA Filing Underway

Chennai, October 23, 2025 (11:15 IST): The share price of Fischer Medical Ventures Ltd (NSE: FISCHER, BSE: 524743) increased by 3.75% reaching an intrady high of ₹103.60 in early trade on Thursday after the company announced that its portfolio company, Nanomedic Technologies, has successfully registered its flagship SpinCare wound treatment system with the UK National Health Service (NHS).

Fischer Medical Ventures Ltd is an Indian medical technology company focused on affordable imaging, diagnostics, and advanced healthcare solutions. The company leverages innovation and strategic partnerships to expand access to modern medical technology across emerging markets. The company is registered on the stock exchange under the tickers FISCHER and 524743 for NSE and BSE, respectively.

Expansion of Global Footprint

The registration has expanded the company’s global footprint to 34 countries and set the stage for commercial launches in India and the United States. To ensure global success, the company has been working proactively to obtain all key regulatory permissions. The company has initiated collaboration with one of London’s largest hospitals as part of its UK expansion strategy. In Europe, MDR/MDD renewal nears completion, with phase one audit completed and phase two scheduled to conclude by mid-October.

In India, all documentation for device registration has been completed, and the company has secured a CDSCO license for clinical investigations, tests, and training. Further, an MD-15 import license application for commercial use has been filed and is awaiting approval. The company is also simultaneously preparing for its US FDA submission, which is led by its newly appointed regulatory leadership.

Market Snapshot

As of October 23, 2025, 11:15 am, shares of Fischer Medical Ventures Ltd were trading at ₹103.13, up by 3.28%, or 3.28 points. The shares of the company have had a decent trading pattern so far, with total traded volume and traded value standing at 0.86 lakh shares and ₹0.87 crore, respectively. The total market cap for the company stood at ₹6,667.39 crore with a positive buy quantity of 1,54,304 shares.

Leadership and Operational Strengthening

To ensure positive results from its recent endeavours, the company has also strengthened its leadership team, which can now support its global scale-up. The company has appointed a Head of Operations, a Head of Business Development and Sales, and a Vice President of Clinical and Regulatory Affairs (North America) to accelerate clinical programs and regulatory filings in key markets.

Clinical Evidence and Real-World Validation

The company has provided clinical evidence and real-world validation data for SpinCare’s safety and efficacy across multiple studies and hospital applications. The retrospective pediatric burns study has been confirmed to be safe and feasible for use. Further, a Stanford-led pilot clinical study reported that it has delivered strong tolerability and wound closure outcomes in epidermolysis bullosa patients. Also, a real-world evaluation observed that there was significant pain reduction, faster healing, and fewer hospital readmissions, which reinforces the device’s clinical utility.

Management Commentary

Showing enthusiasm towards the registration, Ravindran Govindan, Managing Director and Chairman of Fischer Medical Ventures Ltd, said, “The registration with the NHS marks a pivotal moment in Nanomedic’s global journey. With approvals and collaborations in place across key markets, including India and the UK, the company is well-positioned to redefine advanced wound care accessibility worldwide.”

Strategic Outlook

The recent registration with the UK NHS has enabled Nanomedic to advance toward multi-region commercialisation. Now the company can target burn and chronic wound care segments. The company is also working with Indian government hospitals to establish standardised clinical protocols for non-commercial trials with an aim to reduce treatment costs and improve patient outcomes.

REF:https://nsearchives.nseindia.com/corporate/FISCHER_23102025091220_PressreleasewithCL.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations